Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Harrow Health, Inc.NASDAQ: HROW

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$16.5M, compared with -$6.69M a year earlier. Trailing-twelve-month EBITDA was $31.47M.

Context

  • EBITDA amounted to 15.2% of revenue in FY2025, up 4.1 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of $49.79M (+20.4%) for the fiscal year ending Dec 2026, a slowdown from the +86.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$16.5M-181.0% QoQ
Last fiscal yearDec 2025
$41.36M+86.9% YoY
LTMMar 2026
$31.47M+78.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-146.4%-65.2%+81.2 pp
1 year+86.9%+20.4%-66.6 pp
3-year CAGR—+93.3%—
5-year CAGR+65.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
41.36M USD
Year-over-year change
+86.9%
4-year CAGR
+68.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How HROW compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +78.4% is the highest of 8, against a peer median of -55.5%.
  • EBITDA amounts to 11.7% of revenue for HROW, versus a peer median of 1971.1%.
HROW Competitors
EBITDA for HROW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$742M USD+61.3%-3.6%13.9%
HROWHarrow Health, Inc.LTM Mar 2026$31.47M USD+78.4%—11.7%
TTRXTurn Therapeutics Inc.LTM Mar 2026-$3.79M USD———
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$62.08M USD-482.8%—18634.1%
OCSOculis Holding AGLTM Mar 2026-CHF 94.13M CHF+7.5%—18676.3%
KODKodiak Sciences Inc.LTM Sep 2026-$225.15M USD-18.0%——
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$260.06M USD-79.4%—3415.1%
OCULOcular Therapeutix, Inc.LTM Mar 2026-$274.24M USD-55.5%—527.0%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026-$686.8M USD-845.4%—100.7%
Peer median (excluding HROW) —-55.5%-3.6%1971.1%

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.48M88.6M130.19M199.61M272.3M
Cost of Revenue18.21M25.38M39.64M49.25M67.93M
Gross Profit54.26M63.21M90.55M150.37M204.37M
Gross Margin74.9%71.3%69.6%75.3%75.1%
Research & Development11.08M3.05M6.65M12.23M12.85M
Selling, General & Admin39.82M000152.91M
Operating Expenses52.65M61.29M90.12M141.55M165.76M
Depreciation & Amortization1.74M2.83M11.14M13.05M18.91M
EBITDA5.1M(3.94M)11.95M22.13M41.36M
EBITDA Margin7.0%-4.4%9.2%11.1%15.2%
Operating Income1.61M1.92M431K8.82M38.61M
Operating Margin2.2%2.2%0.3%4.4%14.2%
Interest Income00000
Interest Expense5.44M7.24M21.32M22.79M24.18M
Other Income / Expenses(19.49M)(15.93M)(24.14M)(26.14M)(40.33M)
Income Before Tax(17.87M)(14.01M)(23.71M)(17.32M)(1.72M)
Pre-Tax Margin-24.7%-15.8%-18.2%-8.7%-0.6%
Income Tax Expense133K75K701K161K3.42M
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Net Margin-24.8%-15.9%-18.7%-8.8%-1.9%
EPS (Basic)(0.69)(0.51)(0.75)(0.49)(0.14)
EPS (Diluted)(0.69)(0.51)(0.75)(0.49)(0.14)
Weighted Avg Shares26.76M27.46M32.62M35.65M36.76M
Weighted Avg Shares (Diluted)26.76M27.46M32.62M35.65M36.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.